Liposomal Grb2 ASO treatment decreased cell growth in EGFR-overexpressing breast cancer cells, and liposomal Bcl-2 ASO treatment resulted in a significant induction of apoptosis in 11 of 19 patient samples [102]. Here, GRB2 is linked to breast cancer.